Plaquenil
NDC Package 67296-1781-1

11-digit billing NDC: 67296178101

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Plaquenil is use of PLAQUENIL is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. Marketed by Redpharm Drug, Inc., this product is identified by NDC 67296-1781 and is authorized under FDA application NDA009768.

Identification & Billing

NDC Package Code
67296-1781-1
Package Description
12 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
67296178101
RxNorm Crosswalk
  • RxCUI: 979092 - hydroxychloroquine sulfate 200 MG Oral Tablet
  • RxCUI: 979092 - hydroxychloroquine sulfate 200 MG (as hydroxychloroquine 155 MG) Oral Tablet
  • RxCUI: 979094 - Plaquenil 200 MG Oral Tablet
  • RxCUI: 979094 - hydroxychloroquine sulfate 200 MG Oral Tablet [Plaquenil]

Clinical Specifications

Proprietary Name
Plaquenil
Dosage Form
-
Usage Information
Use of PLAQUENIL is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.

Regulatory & Marketing

Labeler Name
Redpharm Drug, Inc.
FDA Application #
NDA009768
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-01-2020
Listing Expiration
12-31-2023
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67296-1781-1 identifies a specific commercial package of 12 tablet in 1 bottle of Plaquenil, labeled by Redpharm Drug, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Redpharm Drug, Inc. on January 01, 2020. The current certification is valid through December 31, 2023.

How is this Redpharm Drug, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67296178101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67296-1781-1
11-Digit CMS (5-4-2)
67296-1781-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.